EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA , and Serum M‐Protein in Relapsed/Refractory Multiple Myeloma

John D Clements iD, Inmaculada C Sorribes iD, Josh Kaullen, Christine Neumar iD, Adekemi Taylor iD, Mun Sang Yue, Xi Chen, Herbert Struemper iD, Geraldine Ferron-Brady iD

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von John D Clements und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Clinical Pharmacology Modeling and Simulation, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B-Cell Maturation Antigen, Models, Biological, Multiple Myeloma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A simultaneous pharmacokinetic (PK)/pharmacodynamic (PD) analysis was conducted to characterize relationships between anti‐B‐cell maturation antigen (BCMA)‐targeting antibody‐drug conjugate, belantamab mafodotin, and longitudinal multiple myeloma (MM) disease markers (soluble BCMA [sBCMA], M‐protein). Data from patients with relapsed/refractory MM receiving belantamab mafodotin monotherapy in the DREAMM‐1 (NCT02064387), DREAMM‐2 (NCT03525678), DREAMM‐3 (NCT04162210), or DREAMM‐5 (NCT04126200) trials were included. The dataset contained 510 patients with 15,860 PK and PD observations. Previous population PK and M‐protein PD models were combined to create a new starting model. Overparameterization was reduced using sensitivity analyses to create a 2‐compartment base model for belantamab mafodotin with a linear clearance component and target‐mediated drug disposition assuming quasi‐equilibrium between belantamab mafodotin and sBCMA binding. Free belantamab mafodotin affected M‐protein elimination rate via a direct effect, and M‐protein in turn scaled sBCMA synthesis rate. sBCMA was assumed to transfer into the central free sBCMA compartment through a reservoir compartment, allowing capture of observed differences in timescales. Stepwise covariate modeling led to the final model, which contained eight covariate effects (baseline sBCMA, albumin, body weight, and sex on belantamab mafodotin clearance; baseline body weight and sex on belantamab mafodotin central volume of distribution; extramedullary disease at screening and baseline sBCMA on M‐protein death rate constant). Simulations of belantamab mafodotin doses/schedules showed concentrations of free sBCMA and M‐protein decreased as free and total belantamab mafodotin increased with higher doses. The PKPD model captured the clearance of belantamab mafodotin and the highly dynamic interactions between belantamab mafodotin PK, M‐protein, and sBCMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedB-Cell Maturation AntigenModels, BiologicalMultiple MyelomaMyeloma ProteinsAgedFemaleHumansMaleMiddle AgedClinical Trials as Topic

Stichwörter der Autor:innen

NONMEMmodelingoncologypharmacodynamicspharmacokineticspopulation pharmacokinetics‐pharmacodynamics

Substanzen

Antibodies, Monoclonal, HumanizedB-Cell Maturation Antigenbelantamab mafodotinMyeloma ProteinsTNFRSF17 protein, human

Autor:innen und Institutionen

  • GSK, Clinical Pharmacology Modeling and Simulation, Collegeville, Pennsylvania, USA.
  • Certara Drug Development Solutions, Certara USA, Inc., Radnor, Pennsylvania, USA.
  • Quantitative Pharmacology and Pharmacometrics Immune/Oncology (QP2-I/O), Merck & Co., Inc., Rahway, New Jersey, USA.
  • Quantitative Clinical Pharmacology, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
  • Exelixis Inc, Alameda, California, USA.
  • GSK, Clinical Pharmacology Modeling and Simulation, Durham, North Carolina, USA.

ORCID-Profile: John D Clements, Inmaculada C Sorribes, Christine Neumar, Adekemi Taylor, Herbert Struemper, Geraldine Ferron-Brady

Förderung

  • GSK
  • GlaxoSmithKline

Zitieren

APA

Clements, J. D., Sorribes, I. C., Kaullen, J., Neumar, C., Taylor, A., Yue, M. S., Chen, X., Struemper, H., & Ferron-Brady, G. (2026). Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA , and Serum M‐Protein in Relapsed/Refractory Multiple Myeloma. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70337

Vancouver

Clements JD, Sorribes IC, Kaullen J, Neumar C, Taylor A, Yue MS, et al. Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA , and Serum M‐Protein in Relapsed/Refractory Multiple Myeloma. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70337

BibTeX
@article{Clements2026,
  author = {Clements, John D and Sorribes, Inmaculada C and Kaullen, Josh and Neumar, Christine and Taylor, Adekemi and Yue, Mun Sang and Chen, Xi and Struemper, Herbert and Ferron-Brady, Geraldine},
  title = {Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA , and Serum M‐Protein in Relapsed/Refractory Multiple Myeloma},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70337}
}
Kostenlos starten →